XL413 is a potent ATP-competitive inhibitor of the important DNA replication initiation kinase Cdc7 (DDK). It increases the efficiency of homology directed DNA repair in CRISPR-Cas9 gene editing. XL413 acted synergistically with other chemotherapy agents in various cancer models.
Shipping: Available products typically ship within 24/48h, via priority shipping.
Do you need support? Contact Customer Service or Technical Support.
Online Account
Access or Create Your Account
Regulatory Status |
RUO – Research Use Only |
---|